Enlonstobart
As of the edition of 20 October 2026, Enlonstobart is an antibody: in active development; acts on PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 23, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Pregnancy and women's health; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDCD1 | Programmed cell death protein 1 | Q15116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 17 | 0 | 11 | 1 |
| Phase 3 | 5 | 0 | 4 | 0 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cspc | Lead sponsor of trials | 2019 to now |
| Shanghai JMT-Bio | Lead sponsor of trials | 2024 to now |